Aarti Drugs Limited
Valuation (94/100) does the heavy lifting; financial trend (28/100) is the drag.
Buy zoneStocksWizard rates Aarti Drugs Limited a Buy, scoring 63/100 on our blended model. On 18.9x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 18% below its 52-week high of ₹522.55 and 33% above the low of ₹319.75. Financial health scores 63/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9. The average analyst target of ₹439 implies about 3% upside across 1 analysts. It clears 7 of 13 investability checks, with durability 47, valuation 87 and momentum 75 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹648.93. Low-confidence estimate — limited data.
Analyst views
1-year price
EOD · 2026-09-1552-week range
-18.41% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy63Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 13.4%
- Pass: Low debt (D/E < 0.5): 0.37x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 6%
- Fail: Earnings growing: -12%
- Fail: Net margin ≥ 10%: 7.6%
- Pass: Current ratio > 1.5: 1.59
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 3.51
- Fail: Piotroski ≥ 7: 6/9
Quarterly results
Annual financials
Shareholding
- Promoter60.2%
- Institutions11.1%
- Public & other28.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 3.51.
Opportunities
- Trading in our value buy zone versus sector peers.
- Trades ~90% below our estimated fair value.
Bear case
Threats
- Earnings contracting year on year.
About Aarti Drugs Limited
Aarti Drugs Limited manufactures and markets active pharmaceutical ingredients, pharmaceutical intermediates, specialty chemicals, and formulations across India and international markets through its subsidiaries. The company produces a range of APIs including aceclofenac, celecoxib, diclofenac variants, nimesulide, and fluoroquinolone compounds such as ciprofloxacin HCL, levofloxacin base, and norfloxacin.
Aarti Drugs Limited — frequently asked questions
Is Aarti Drugs Limited a buy, hold or sell?
StocksWizard currently rates Aarti Drugs Limited (AARTIDRUGS) a Buy, based on a blended score of 63/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Aarti Drugs Limited's fair value?
Our blended DCF and relative-valuation model estimates Aarti Drugs Limited's fair value at about ₹811.17, versus a current price of ₹426.35 — roughly 90% upside. On that basis the stock looks undervalued by 90%.
Is Aarti Drugs Limited financially healthy?
Aarti Drugs Limited scores 63/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has Aarti Drugs Limited's share price performed?
Aarti Drugs Limited is up 15% over three months, and last traded at ₹426.35. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.